» Authors » Christina Minnick

Christina Minnick

Explore the profile of Christina Minnick including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 4
Citations 59
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Loughran H, Schirripa K, Roecker A, Breslin M, Tong L, Fillgrove K, et al.
ACS Med Chem Lett . 2024 Jan; 15(1):123-131. PMID: 38229758
Inhibition of glucosylceramide synthase (GCS) has been proposed as a therapeutic strategy for the treatment of Parkinson's Disease (PD), particularly in patients where glycosphingolipid accumulation and lysosomal impairment are thought...
2.
Roecker A, Schirripa K, Loughran H, Tong L, Liang T, Fillgrove K, et al.
ACS Med Chem Lett . 2023 Feb; 14(2):146-155. PMID: 36793422
Parkinson's disease is the second most prevalent progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. Loss-of-function mutations in GBA, the gene that encodes for...
3.
Cosden M, Jinn S, Yao L, Gretzula C, Kandebo M, Toolan D, et al.
Neurobiol Dis . 2021 Sep; 159:105507. PMID: 34509608
Mutations in the lysosomal enzyme glucocerebrosidase (GCase, GBA1 gene) are the most common genetic risk factor for developing Parkinson's disease (PD). GCase metabolizes the glycosphingolipids glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph)....
4.
Hong C, Byrne N, Zamlynny B, Tummala S, Xiao L, Shipman J, et al.
Nat Commun . 2021 Feb; 12(1):815. PMID: 33547286
Narcolepsy type 1 (NT1) is a chronic neurological disorder that impairs the brain's ability to control sleep-wake cycles. Current therapies are limited to the management of symptoms with modest effectiveness...